|
Misteltherapie bei Krebs: im Tiermodell
gelang es nun erstmalig auf
molekularer Ebene im Fall einer
lymphoblastischen Leukämie die Wirksamkeit der
Therapie mit einem Mistelextrakt nachzuweisen.
An der Universitätsklinik Charite, Berlin,
konnte gezeigt werden, dass der
programmierte Zelltod (Apoptosis) dosisabhängig
ist und durch den Mistelwirkstoff ausgelöst
werden kann.
Mehr Informationen zum
Thema Misteltherapie bei Krebs finden Sie
auf
diesen Websites
hier
Die vollständige englischsprachige
Kurzversion dieser Studie (sog. MEDLINE
Abstract) finden Sie
hier
Titel: Molecular mechanisms of mistletoe
plant extract-induced apoptosis in acute
lymphoblastic leukemia in vivo and in vitro.
Journal: Cancer Lett. 2008 Jun 18; 264(2):
218-28.
Autor(en): Seifert G, Jesse
P, Laengler A, Reindl T, Lüth M, Lobitz S, Henze
G, Prokop A, Lode HN
Bezug: Department of Pediatric Oncology/Hematology,
Otto-Heubner-Center for Pediatric and Adolescent
Medicine (OHC), Charité, Universitätsmedizin
Berlin, Germany.
Abstract:
Viscum album (Mistletoe) is one of the most
widely used alternative cancer therapies.
Aqueous mistletoe extracts (MT) contain the three mistletoe lectins I, II and III as one
predominant group of biologically active agents.
Although MT is widely used, there is a lack of
scientifically sound preclinical and clinical
data. In this paper, we describe for the first
time the in vivo efficacy and mechanism of
action of MT in lymphoblastic leukemia.
For this purpose, we first
investigated both the cytotoxic effect and the
mechanism of action of two standardized aqueous
MTs (MT obtained from fir trees (MT-A); MT
obtained from pine trees (MT-P)) in a human
acute lymphoblastic leukemia (ALL) cell line
(NALM-6). MT-A, MT-P and ML-I inhibited
cell proliferation as determined by Casy((R))
Count analysis at very low concentrations with
MT-P being the most cytotoxic extract.
DNA-fragmentation assays
indicated that dose-dependent induction of
apoptosis was the main mechanism of cell
death. Finally, we evaluated the efficacy of
MT-A and MT-P in an in vivo SCID-model of pre-B
ALL (NALM-6).
Both MTs significantly
improved survival (up to 55.4 days) at all
tested concentrations in contrast to controls
(34.6 days) without side effects.
PubMed-ID: 18314258
ISSN: 0304-3835 (Print)
Erstellungsdatum: 06.05.2008
|
